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Rifaximin (Xifaxan) Therapy Initiation During
Hospitalization and Access Facilitation at Discharge
Phuong Phan, PharmD; Theresa Morikawa, PharmD; Adam Saulles, PharmD
Background
•Hepatic encephalopathy (HE) describes a spectrum of
potentially reversible neuropsychiatric abnormalities in
patients with liver dysfunctions or portal systemic shunt.
Patients with overt HE (OHE) often present with
impaired cognition, confusion, personality changes,
impaired memory, or coma.
•The 2014 American Association for Study of Liver
Diseases/European Association for Study of Liver
Diseases guidelines for OHE management recommend
rifaximin as an add-on therapy to lactulose for recurrent
OHE. However, previous data have shown many
patients, who were admitted with OHE-related
problems, did not receive rifaximin as maintenance
outpatient therapy at time of discharge. One major
barrier to this is cost. Prescription benefits frequently
require prior authorization for coverage of rifaximin or
produce large copays. This leads to hesitancy with both
rifaximin therapy initiation during inpatient admission
and/or outpatient continuation upon discharge due to
assumed unaffordability and prior authorization barriers,
despite appropriate indication.
•Recently, a transition-of-care program, Discharge
Medication Access Services (DMAS), was developed and
implemented by Health System integrated Outpatient
Pharmacies (HSOPs) at two tertiary hospitals to minimize
this interruption and encourage appropriate guidelinebased prescribing. This service proactively identifies and
resolves coverage and affordability barriers for patients
initiated on high-cost medications, such as rifaximin,
during their admission.
•h OHE.
Purpose
• To evaluate the impact of the DMAS implementation
on rifaximin access at discharge in patients with OHE

Discussion
Results

Baseline Characteristics

Mean age (SD)

TOTAL
(N = 44)
60.09 (10.91)

PRE-DMAS
(n = 17)
60.24 (10.15)

POST-DMAS
(n = 27)
60 (11.55)

Female (n, %)

20 (45.45)

6 (35.29)

14 (51.85)

0.345

Patients indicated for
rifaximin
continuation upon
discharge (n, %)

34 (77.27)

13 (76.47)

21 (77.78)

1

P value
0.945

Outcome Summary

Primary outcome
Successful first fill at HSOPs
(n, %)
Secondary outcomes
Intervention documented
(n, %)
Prescription at discharge
(n, %)
Refill at HSOPs (n, %)

TOTAL
(N = 44)

PRE-DMAS
(n = 17)

POST-DMAS
(n = 27)

P value

8 (23.53)

2 (15.38)

6 (28.57)

0.449

14 (41.18)

0

14 (66.67)

<0.001

28 (82.35)

11 (84.62)

17 (80.95)

1

1 (2.94)

0

1 (4.76)

1

Outcomes
• Primary outcomes
• Percentage of patients with indication for rifaximin
continuation at discharge who
successfully accessed rifaximin pre- and postimplementation of DMAS
• Secondary outcomes
•Percentage of patients with interventions pre- and
post- DMAS
•Percentage of patients with rifaximin prescribed at
discharge
•Patient retention rate after discharge (defined as
patients with at least one refill dispensed at HSOPs)
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Limitations
•Retrospective study with small sample size. As a result,
the study was underpowered for assessing primary and
secondary outcomes
•This data is limited to patients who opted to use HSOP
services only; thus, patients who successfully filled their
rifaximin prescriptions at other pharmacies were not
represented
•Prescribing hesitancy due to high cost of rifaximin
appears to be present, however, insufficient documented
information limited the ability to thoroughly assess this
aspect from chart review only
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Going Forward
•Developing a survey to identify any prescribing hesitancy
among inpatient providers due to high cost
•If prescribing hesitancy confirmed, consider providing
education to providers regarding DMAS service and how
the program can proactively facilitate access prior to
discharge to ensure patients will be able to timely fill
prescriptions at time of discharge
•Larger study size is needed to assess the significance of
the primary and secondary outcomes
•Another area to evaluate in the future is cost analysis
and cost savings before and after DMAS implementation

Methods
•Study design
•Retrospective chart review
•Study period: Oct 1st, 2020 – Oct 31st, 2021
•Pre-DMAS: Oct 1st, 2020-Mar 29th, 2021
•Post-DMAS: Mar 29th, 2021 – Oct 31st, 2021
•Inclusion criteria
•Adults (≥18 years) with history of OHE admitted to
two tertiary hospitals during the defined time periods
•Active lactulose orders and initiated on rifaximin
during admission
•Exclusion criteria
•Pediatric patients (age <18 years)
•Had an active order of rifaximin prior to admission
•Expired during hospital admission
•DMAS intervention
•Defined as obtaining a prescription override or
attempting a prior authorization by pharmacy
technicians at HSOPs and documented in patients’
electronic health records

• Patient baseline characteristics were similar between
groups
• Total of 44 patients were included
• Mean age 60 years old
• 77% of patients indicated for rifaximin continuation
upon discharge
• Primary outcomes
• No significant difference before and after DMAS
implementation when assessing the rate of successful
access to the first fill of rifaximin via HSOPs at
discharge (15% pre-DMAS vs. 28% post-DMAS)
• Secondary outcomes
•In the post-implementation phase, among 21 patients
indicated to continue rifaximin at discharge, 14
patients (67%) had pharmacy interventions to facilitate
access at discharge. This could be because
some patients opted not to use HSOP service or loss to
follow up.
•No significant difference in the percentage of rifaximin
prescriptions at discharge before and after DMAS
implementation or patient retention rate. In the preDMAS period, no patients were identified to return for
prescription refills. In the post-DMAS period, among 6
patients with first fill at HSOPs, one patient returned
for refills. Possible reasons for low retention rate
include long geographic distance between patient’s
home and HSOPs compared to other local pharmacies,
patient non-adherence and high co-pay.
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